Trials / Completed
CompletedNCT02827903
Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Compare the Efficacy and Safety of Metformin/Rosuvastatin Combination Therapy With Metformin or Rosuvastatin Monotherapy in Patients With Type 2 Diabetes and Dyslipidemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 237 (actual)
- Sponsor
- Jeil Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Compare the Efficacy and Safety of Metformin/Rosuvastatin Combination Therapy With Metformin or Rosuvastatin Monotherapy in Patients With Type 2 Diabetes and Dyslipidemia
Detailed description
Multi-center, Randomized, Double-blind, Phase III clinical trial
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin + Rosuvastatin | Group I: Metformin + Rosuvastatin, |
| DRUG | Metformin + placebo | Group II: Metformin + placebo, |
| DRUG | placebo + Rosuvastatin | Group III: placebo + Rosuvastatin |
Timeline
- Start date
- 2016-01-15
- Primary completion
- 2017-11-21
- Completion
- 2018-03-16
- First posted
- 2016-07-11
- Last updated
- 2018-07-06
Locations
33 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02827903. Inclusion in this directory is not an endorsement.